NCT07307287

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: NOT_YET_RECRUITING

Phase: PHASE2

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer, Early Breast Cancer, Locally Advanced Breast Cancer

Signal summary

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: rare_population_signal

Stopped reason

No stop reason available in the current public record.